Latest Breaking News On - பசி தேசிய நிறுவனம் ஆஃப் மருந்தகம் - Page 15 : vimarsana.com

Share this article Share this article Continues to boost production capacity to meet increasing demand Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination Vaccines provide timely mass protection for adults aged 18 and above, including those over 60 TIANJIN, China, March 22, 2021 /PRNewswire/  CanSinoBIO Biologics Inc. ( CanSinoBIO ) (HKEX: 06185) today announced that the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI) granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ( Ad5-nCoV , trade name: Convidecia™). The approval is based on the vaccine s interim results for Phase III clinical trial and marks the first approval of Convidecia™ in an European Union member state.

Shanghai pharmaceuticalsCansinobio biologics incCommission for protectionDrug regulatory authority of pakistanEuropean unionHungarian national institute of pharmacyNational medical products administration of chinaHungarian national instituteRecombinant novel coronavirus vaccineAdenovirus typeChief executive officerNational medical products administrationFederal commissionSanitary risksDrug regulatory authorityExecutive director